|Bid||0.0000 x 3200|
|Ask||1.7600 x 800|
|Day's Range||1.5152 - 1.5600|
|52 Week Range||1.1500 - 3.6700|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2020 - Nov 16, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.20|
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He, Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the following upcoming virtual conferences in September. Details for the virtual conferences are as follows.
Some CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders are probably rather concerned to see the share price fall...
By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals (NASDAQ:CASI) signaled a shift in its business strategy in March – focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASI’s initial broad-reaching goal to be the leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the